PTN

Business Context and Reporting Period

Company: Palatin Technologies, Inc. (PTN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Six months ended December 31, 2024
Business Overview: Palatin is a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system. The Company sold worldwide rights to its commercial product, Vyleesi, to Cosette Pharmaceuticals in December 2023. Current development focuses on obesity (bremelanotide with tirzepatide), dry eye disease (PL9643), and ulcerative colitis (PL8177).

Key Financial Metrics

Debt and Liquidity: The Company has no long-term debt but holds significant current liabilities, including accounts payable of $6.7 million and accrued expenses of $1.7 million. Cash burn from operations remains high, though improved slightly year-over-year.

Material Changes vs. Prior Period

• Revenue Elimination: Product revenue dropped to $0 for the six months ended December 31, 2024, compared to $4.1 million in the prior year, following the December 2023 sale of Vyleesi assets to Cosette Pharmaceuticals.
• Gain on Sale: The Company recognized a $2.5 million gain on the sale of Vyleesi in the current period (settlement of purchase commitments), compared to a $7.8 million gain in the prior period (upfront purchase price).
• Expense Reduction: Research and Development (R&D) expenses decreased to $9.2 million from $10.6 million, and Selling, General, and Administrative (SG&A) expenses decreased to $3.7 million from $6.2 million, primarily due to the elimination of Vyleesi-related selling costs.
• Warrant Exercises: Financing activities included $3.4 million in proceeds from warrant exercises in the current period, compared to minimal proceeds in the prior period.

Outlook, Risks, and Management Commentary

Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for one year from the date of the filing. This is due to an accumulated deficit of $452 million and current liabilities exceeding current assets. The Company expects existing cash to fund operations into the second half of 2025 but requires additional financing.

Recent Financing: In a subsequent event (February 10, 2025), the Company entered into an agreement for a registered direct offering of 4,688,000 shares at $1.00 per share, raising approximately $4.7 million.

Clinical Pipeline Updates:

• Obesity: Phase 2 trial for bremelanotide co-administered with tirzepatide completed in Q4 2024; topline results expected Q1 2025.
• Dry Eye Disease (PL9643): Phase 3 trial completed; positive Type C meeting with FDA concluded. Patient enrollment for next phase could commence H1 2025.
• Ulcerative Colitis (PL8177): Phase 2 trial ongoing; topline results expected Q1 2025.

Listing Compliance Risk: The Company is not in compliance with NYSE American continued listing standards regarding stockholders' equity. A compliance plan has been accepted with a deadline of April 10, 2025. Failure to regain compliance may result in delisting.

Internal Controls: Management disclosed that disclosure controls and procedures were not effective due to a material weakness in accounting for complex financial instruments.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $3.4 million cash balance plus the $4.7 million subsequent financing to cover the projected burn rate through H2 2025.
• Listing Status: Monitor progress toward regaining NYSE American compliance by the April 10, 2025 deadline to avoid delisting.
• Clinical Milestones: Track the release of topline data for the obesity (Q1 2025) and ulcerative colitis (Q1 2025) programs, which are critical for future valuation.
• Contractual Obligations: Review the $2.5 million in inventory purchase commitments related to Vyleesi manufacturing, which remain as liabilities despite the asset sale.
• Internal Controls: Assess the remediation plan for the material weakness in financial reporting controls.